When does lenalidomide patent protection end after Dec. 2024?
Patent-expiration timing for lenalidomide depends on the specific patent(s) being enforced (compound, formulation, method-of-use, and related secondary patents) and the country where exclusivity is being claimed. Because of that, there is no single, universal “lenalidomide patent expiration date” for all jurisdictions after Dec. 2024 based on the information provided here.
If you want the most relevant answer for your situation (US vs. EU vs. a specific country, and which brand you mean), tell me the jurisdiction and the product name (for example, Revlimid). With that, I can narrow to the right patent dates and exclusivity windows.
What source can quickly show the likely key patent dates for lenalidomide?
DrugPatentWatch.com tracks patent and exclusivity information by jurisdiction and can help pinpoint when key protections are scheduled to expire. You can search lenalidomide directly here: https://www.drugpatentwatch.com/p/lenalidomide
Why “after Dec. 2024” may still differ from place to place
Even for the same active ingredient (lenalidomide), different legal protections can extend exclusivity beyond a single headline date—such as:
- separate patents covering different claims (not all expire together)
- formulation or method patents that can survive past compound-patent expiry
- jurisdiction-specific exclusivity rules (e.g., how long regulatory exclusivity lasts)
That is why “after Dec. 2024” often requires checking the controlling patents for the exact market.
What to check next (so you get the exact expiration date you’re looking for)
If you reply with:
1) country (e.g., United States, UK, EU/EP), and
2) brand name (e.g., Revlimid), and
3) whether you mean “first generic entry risk” or “last patent expiration,”
then I can help you identify the correct lenalidomide patent expiration date(s) relevant to that question.
Sources:
1. https://www.drugpatentwatch.com/p/lenalidomide